chartexchange

BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

PR Newswire | Nov 18, 2026 7:00 AM EST

- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties - - Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is currently enrolling the fourth of five planned dosing cohorts - - BioLineRx...

Read original article